--- title: "Bristol-Myers' $15.2B Hengrui Deal: Holder Read" type: news slug: bristol-myers-hengrui-15-2b-licensing-holder-read-2025q4 canonical_url: https://13finsight.com/news/bristol-myers-hengrui-15-2b-licensing-holder-read-2025q4 published_at: 2026-05-12T18:52:08.046Z updated_at: 2026-05-12T18:52:11.052Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 825 locale: en source: 13F Insight --- # Bristol-Myers' $15.2B Hengrui Deal: Holder Read > Bristol-Myers Squibb has signed a licensing agreement with Hengrui Pharma worth up to $15.2 billion across 13 assets. The 13F ownership data shows two deep-value houses already running outsized concentrated positions in BMY before the pact landed. Bristol-Myers Squibb has signed a licensing agreement with Hengrui Pharma covering 13 assets and worth up to $15.2 billion in milestone payments, according to coverage from Endpoints News. The deal is one of the largest single-counterparty pharma licensing transactions of the cycle, and it lands on a name where the 13F ownership data already told a very specific story about institutional conviction in BMY's pipeline reset.Our holdings tape shows BMY sitting on 2,649 reporting 13F filers through 2025Q4, with $89.6B of aggregated institutional value. The two most aggressive active positions in that base are not generalist large-caps — they are concentrated value houses that have spent the last two years arguing the patent-cliff narrative was being mispriced. Independent Franchise Partners runs BMY at a 7.14% portfolio weight across 20.8 million shares. Pzena Investment Management runs the name at a 3.37% weight across 17.1 million shares. Those are the conviction sizes you see when a manager has separately modeled the cliff-replacement scenario and concluded the bargain price already discounts a worse outcome than what the company actually executes.The Hengrui pact is the kind of capital event that those two holders would have written into their thesis as upside optionality, not as a base case. The deal structure — large headline dollar value backloaded as milestones across 13 assets — mirrors the standard Chinese-pharma in-licensing model that BMY's competitors used heavily in 2024 and 2025 to backfill late-stage pipeline at lower upfront cost than de novo M&A.The holder mix is built for patienceThe top of BMY's 13F list is dominated by mandate-driven holders. BlackRock reports $9.5B of value, Vanguard Capital Management reports $8.0B, State Street reports $5.3B, and the Charles Schwab Investment Management passive book reports another $3.8B at a 0.60% portfolio weight. These are index-mimicking exposures; they will not vote with their feet on a licensing headline.The 16 active managers in the top 20 are where the signal lives. Beyond Independent Franchise Partners and Pzena, PRIMECAP Management reports a 1.19% portfolio weight, AQR Capital runs $1.4B of value at a 0.73% weight, and Capital International Investors sits at $1.1B. The 2025Q4 reports show all five of those names holding through the late-2025 patent-cliff narrative without trimming.13D/G tape: the disclosure picture is shiftingBMY has one active 13D/G filing on the SEC tape, and it tracks the same passive consolidation we have flagged in other large-cap names. Vanguard Capital Management LLC filed SC 13G accession 0002100119-26-000248 on April 29, 2026 disclosing 7.49% beneficial ownership via 132,320,240 shares. The companion exit amendment by the older Vanguard Group entity (CIK 0000102909) was filed in late March 2026. As with our parallel read on the GM cap table, this is structural rather than directional — an internal Vanguard reorganization, not a fresh conviction call.The other recent disclosure of note is BMY itself filing SC 13G/A accession 0000019617-25-001051 on October 31, 2025, reporting 4.00% — a routine treasury reporting filing that does not change the active-conviction picture. No activist filer has surfaced on the cap table, which means the strategic moves the company is making (Hengrui pact included) are management-initiated rather than coerced.What changes after a $15.2B licensing pactThe mechanical question for the 13F holders is whether the milestone structure of the Hengrui deal is dilutive to near-term free cash flow or accretive once the asset list ships into Phase III. The biotech licensing math is well understood: large headline values do not flow through the income statement up-front; they flow through R&D expense as opt-ins fire and clinical readouts hit. BMY's investor relations briefing on the deal will be the first chance to see how management has front-loaded the upfront component versus the back-loaded milestones, and how it sequences the 13 assets against the existing patent-cliff calendar.The follow-on test for the holder base is the 2026 Q1 13F deadline on May 15, 2026. That cycle captures filings dated March 31, 2026 — the period just before the Hengrui pact landed. The cycle that will reveal whether Independent Franchise Partners and Pzena treat the licensing as thesis-validating versus capital-burn closes on August 14, 2026. If either fund trims from its current size, that is a thesis break we will flag in real time.What to watchThree concrete anchors. First, BMY's Q2 2026 earnings release in late July 2026 will be the first reported quarter that contains the partial upfront from Hengrui. Second, the 2026 Q2 13F cycle (filings due August 14) is the first that captures how the active-conviction names traded the headline. Third, watch for additional 13G filings from foreign sovereign wealth or Asia-domiciled mutual fund complexes — cross-border pharma licensing deals of this size occasionally pull in regional allocators who treat the partner-company exposure as a paired bet.The headline reads as a big number. The ownership data reads as a story about two value houses already underwriting the patent-cliff bridge well before management proved it could pull off a deal of this scale.See the full 2,649 institutional holders of BMY → ## FAQ ### How big is the Bristol-Myers Hengrui licensing deal? The licensing agreement covers 13 drug assets and is worth up to $15.2 billion in milestone payments to Hengrui Pharma, per coverage in Endpoints News. The headline value is backloaded; only a portion is paid up-front, with the remainder tied to clinical and regulatory milestones. ### Who are the most concentrated active holders of BMY? Independent Franchise Partners runs BMY at a 7.14% portfolio weight across 20.8 million shares, and Pzena Investment Management runs the name at a 3.37% weight across 17.1 million shares. Those are conviction-grade sizes that signal the active managers have already underwritten the patent-cliff bridge. ### When will the Hengrui deal show up in BMY 13F filings? The first 13F cycle that captures institutional reaction to the licensing pact closes August 14, 2026, covering filings dated June 30, 2026. The May 15, 2026 cycle reflects the period just before the deal was announced. ### Is there activist pressure on Bristol-Myers Squibb? No activist 13D filer is currently on the BMY cap table. The strategic moves the company is making, including the Hengrui pact, are management-initiated rather than coerced by an external campaign. --- Source: 13F Insight — https://13finsight.com/news/bristol-myers-hengrui-15-2b-licensing-holder-read-2025q4 Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-12T18:52:11.052Z